In the G7 mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK), Hoffmann-Krueger epidemiologists expect the incident cases of prostate cancer to increase from 462 307 cases in 2012 to 560 640 cases in 2022.
Scope: G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK)
10-year patient population forecast + 5 years of historical data
Key Users: Oncology Market Research - New Product Planning - Business Development & Licensing
Oncology Market Access – Oncology Marketing leaders
Insight: Insight into the prostate cancer strategy and business development activities
Transparent forecasts methodology and assumptions
Concise and comparable analysis
Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.
The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.
Reasons To Buy
Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.